Browsing by Yonsei Author : Sohn, Joo Hyuk

eperson profile image
Sohn, Joo Hyuk [손주혁]
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (15045889800)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 158

This table browses all dspace content
Issue DateTitleJournal Title
2023Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) EUROPEAN JOURNAL OF CANCER
2023Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
2023A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy CANCER RESEARCH AND TREATMENT
2023Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer CANCER RESEARCH AND TREATMENT
2023Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features DIAGNOSTICS
2023Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2023Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer ESMO OPEN
2023Capivasertib in Hormone Receptor-Positive Advanced Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2023A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) CANCER RESEARCH AND TREATMENT
2023Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA NATURE COMMUNICATIONS
2023Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerEUROPEAN JOURNAL OF CANCER
2023Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2 CANCER SCIENCE
2023Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) CANCER RESEARCH AND TREATMENT
2023Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
2023On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates BREAST CANCER RESEARCH
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2023Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP CANCER MEDICINE
2022Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)BREAST
2022Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialJOURNAL OF CLINICAL ONCOLOGY
2022Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial JAMA ONCOLOGY
2022Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
2022Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2022Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer CANCERS
2022Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantCLINICAL CANCER RESEARCH
2022Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial ANNALS OF ONCOLOGY
2022Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial CLINICAL CANCER RESEARCH
2021Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study ANNALS OF ONCOLOGY
2021Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study) THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2021MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast CancerCLINICAL CANCER RESEARCH
2021Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)ESMO OPEN
2021Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer PHARMACEUTICALS
2021Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial CANCER RESEARCH AND TREATMENT
2021Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations INVESTIGATIONAL NEW DRUGS
2021Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trialLANCET ONCOLOGY
2021Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer BRITISH JOURNAL OF CANCER
2021Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer INTERNATIONAL JOURNAL OF CANCER
2021Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib JCO PRECISION ONCOLOGY
2021Regarding the article by Rugo Reply ONCOLOGIST
2021Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary PerspectiveANNALS OF SURGERY
2021Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trialsCANCER SCIENCE
2021Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups NPJ BREAST CANCER
2021Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy SCIENTIFIC REPORTS
2021Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer FRONTIERS IN ONCOLOGY
2021Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugsClinical and Translational Science
2021A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis ANNALS OF ONCOLOGY
2021Genomic landscape of extraordinary responses in metastatic breast cancer COMMUNICATIONS BIOLOGY
2021Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO studyEUROPEAN JOURNAL OF CANCER
2021Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 ONCOLOGIST
2021A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast CancerCLINICAL CANCER RESEARCH
2020Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinibBREAST CANCER RESEARCH AND TREATMENT